Loading...
Loading...
ACRS| Name | Value |
|---|---|
| Revenues | 7.8M |
| Cost of Revenue | 1.5M |
| Gross Profit | 6.2M |
| Operating Expense | 28.2M |
| Operating I/L | -22.0M |
| Other Income/Expense | -5.7M |
| Interest Income | 0.0M |
| Pretax | -27.6M |
| Income Tax Expense | 5.7M |
| Net Income/Loss | -33.3M |
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates for immune-inflammatory diseases. The company operates through two segments: Therapeutics, which identifies and develops novel therapies for immuno-inflammatory diseases, and Contract Research, providing laboratory services. Aclaris is developing Zunsemetinib, an MK2 inhibitor for rheumatoid and psoriatic arthritis and Hidradenitis suppurativa, as well as ATI-1777, a soft JAK 1/3 inhibitor for atopic dermatitis. Additionally, the company is working on ATI-2138 for T cell-mediated autoimmune diseases, a Gut-Biased Program for inflammatory bowel disease, and ATI-2231 for pancreatic and metastatic breast cancer.
